143 related articles for article (PubMed ID: 12537978)
1. The in vitro generation of Ph1+ ALL-specific HLA-A24-restricted cytotoxic T lymphocytes using a synthetic 16 mer minor bcr-abl peptide.
Hagihara M; Tsuchiya T; Hyodo O; Ueda Y; Tazume K; Gansuvd B; Kato S; Hotta T
Leuk Res; 2003 Mar; 27(3):253-7. PubMed ID: 12537978
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.
Nieda M; Nicol A; Kikuchi A; Kashiwase K; Taylor K; Suzuki K; Tadokoro K; Juji T
Blood; 1998 Feb; 91(3):977-83. PubMed ID: 9446659
[TBL] [Abstract][Full Text] [Related]
3. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
4. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
[TBL] [Abstract][Full Text] [Related]
5. Characterization of cytomegalovirus pp65-HLA-A24 peptide-specific CTL lines from metastatic melanoma patients.
Akiyama Y; Tai S; Komiyama M; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y
Oncol Rep; 2009 Jul; 22(1):185-91. PubMed ID: 19513522
[TBL] [Abstract][Full Text] [Related]
6. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide.
Ohminami H; Yasukawa M; Fujita S
Blood; 2000 Jan; 95(1):286-93. PubMed ID: 10607714
[TBL] [Abstract][Full Text] [Related]
7. Cytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptide.
Matsunaga K; Nakao M; Masuoka K; Inoue Y; Gouhara R; Imaizumi T; Nishizaka S; Itoh K
Jpn J Cancer Res; 1999 Sep; 90(9):1007-15. PubMed ID: 10551332
[TBL] [Abstract][Full Text] [Related]
8. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.
Yasukawa M; Ohminami H; Kojima K; Hato T; Hasegawa A; Takahashi T; Hirai H; Fujita S
Blood; 2001 Sep; 98(5):1498-505. PubMed ID: 11520800
[TBL] [Abstract][Full Text] [Related]
9. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
[TBL] [Abstract][Full Text] [Related]
10. [Construction of genetically modified dendritic cell vaccine expressing bcr/abl fusion gene and inducing specific cytotoxic T lymphocytes to kill K562 cells in vitro].
Wang WW; Huang RW; Hu Y; Li XD; Wang DN; He Y; Liu JJ
Ai Zheng; 2009 Jun; 28(6):602-6. PubMed ID: 19635197
[TBL] [Abstract][Full Text] [Related]
11. Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.
Berke Z; Andersen MH; Pedersen M; Fugger L; Zeuthen J; Haurum JS
Leukemia; 2000 Mar; 14(3):419-26. PubMed ID: 10720136
[TBL] [Abstract][Full Text] [Related]
12. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte.
Nukaya I; Yasumoto M; Iwasaki T; Ideno M; Sette A; Celis E; Takesako K; Kato I
Int J Cancer; 1999 Jan; 80(1):92-7. PubMed ID: 9935237
[TBL] [Abstract][Full Text] [Related]
13. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients.
Osman Y; Takahashi M; Zheng Z; Koike T; Toba K; Liu A; Furukawa T; Aoki S; Aizawa Y
Leukemia; 1999 Feb; 13(2):166-74. PubMed ID: 10025889
[TBL] [Abstract][Full Text] [Related]
14. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24.
Tanaka F; Fujie T; Tahara K; Mori M; Takesako K; Sette A; Celis E; Akiyoshi T
Cancer Res; 1997 Oct; 57(20):4465-8. PubMed ID: 9377553
[TBL] [Abstract][Full Text] [Related]
15. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
16. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.
Umano Y; Tsunoda T; Tanaka H; Matsuda K; Yamaue H; Tanimura H
Br J Cancer; 2001 Apr; 84(8):1052-7. PubMed ID: 11308253
[TBL] [Abstract][Full Text] [Related]
17. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs.
Gomi S; Nakao M; Niiya F; Imamura Y; Kawano K; Nishizaka S; Hayashi A; Sobao Y; Oizumi K; Itoh K
J Immunol; 1999 Nov; 163(9):4994-5004. PubMed ID: 10528204
[TBL] [Abstract][Full Text] [Related]
18. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
Yasukawa M; Ohminami H; Kaneko S; Yakushijin Y; Nishimura Y; Inokuchi K; Miyakuni T; Nakao S; Kishi K; Kubonishi I; Dan K; Fujita S
Blood; 1998 Nov; 92(9):3355-61. PubMed ID: 9787173
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail.
Akiyama Y; Maruyama K; Nara N; Mochizuki T; Yamamoto A; Yamazaki N; Kawashima I; Nukaya I; Takesako K; Yamaguchi K
Anticancer Res; 2004; 24(2B):571-7. PubMed ID: 15160996
[TBL] [Abstract][Full Text] [Related]
20. Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients.
Kobayashi K; Noguchi M; Itoh K; Harada M
Cancer Sci; 2003 Jul; 94(7):622-7. PubMed ID: 12841872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]